Effect of Obesity on Surgical Outcomes and Survival for Gastric Cancer
Obesity, Gastric Cancer
About this trial
This is an interventional screening trial for Obesity focused on measuring gastric cancer, gastrectomy, laparotomy, surgical outcome, survival, abdominal fat area, Body Mass Index
Eligibility Criteria
Inclusion Criteria:
- Preoperative endoscopy and biopsy confirmed gastric adenocarcinoma, and predictively feasible of conventional open total gastrectomy or subtotal gastrectomy;
- Predictively resectable diseases, of preoperative staging Japanese Gastric Cancer Association 14th Edition clinical T1N0M0-T4aN+M0;
- Age:≤75 years, or ≥18 years;
- Without serious disease and malignance disease;
- Without histories of abdominal surgery;
- World Health Organization performance score ≤2, American Society of Anesthesiologists score ≤3;
- No limit to sexual and race;
- Informed consent required;
- Obesity is defined as BMI≧30kg/m2 or preoperative AFA≧100cm2/cm.
Exclusion Criteria:
- Patients with other severe complications cannot tolerate surgery: such as severe heart and lung diseases, heart function below clinical stage 2, uncontrollable hypertension, pulmonary infection, moderate to severe chronic obstructive pulmonary disease, chronic bronchitis, severe diabetes and / or renal insufficiency, severe hepatitis and / or function below the rank of CHILD B grade, and severe malnutrition, etc;
- Patients treated with neoadjuvant chemotherapy or radiation therapy which might affect the efficacy observation;
- Severity mental diseases;
- Primary lesion cannot be resected in the pattern of transabdominal gastrectomy, but for Whipple's procedure, or with a transthoracic approach surgery;
- After signature the Clinical trial agreement, patients and their agent will quit the trial.
Sites / Locations
- West China HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Other
Experimental
BMI group (Successive patients)
AFA group(Successive patients)
All successive patients meeting the including criteria and signed the informed consent will be measured BMI and the data will be recorded in the prospective database. The formula for BMI is weight in kilograms divided by height in meters squared (kg/m2). the normal range is usually considered to be 18.5 to 24.9, with less than 18.5 considered underweight, more than 25.0 considered overweight and above 30.0 obese. Investigators declare that there exists no conflicts of interest.
All successive patients meeting the including criteria and signed the informed consent will be measured BMI and the data will be recorded in the prospective database. The abdominal fat area at the umbilical level was measured using a CT scanner(sango Mount Monitor Wireless Panel; Siemens , Munich, Germany) while the examinee was in a supine position and estimated using a Volume software (fat Pointer; Siemens , Munich, Germany). The imaging conditions were 120 kilovolt and 50 milliampere, using a 5-mm-thick slice.The areas covered by visceral fat software calculated from pixels with densities ranging from-190 to -30 hounsfield unit. No contrast agent is needed. Patients in the AFA group will be also measured by BMI. Investigators declare that there exists no conflicts of interest.